News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dr. Reddy's Laboratories Ltd. (RDY) Signs Definitive Agreement With 3i For The Strategic Acquisition Of Betapharm Arzneimittel GmbH For Up To $572 Million


2/16/2006 10:31:42 AM

HYDERABAD, India & FRANKFURT, Germany & AUGSBURG, Germany--(BUSINESS WIRE)--Feb. 16, 2006--Dr. Reddy's Laboratories (NYSE: RDY): betapharm is the fourth-largest generics company in Germany and the fastest growing company in the top 10(1). Combination of Dr. Reddy's and betapharm offers an excellent opportunity to build on the unique strengths of each company to emerge as a leading generics player in Europe in the long- term. Dr. Reddy's and 3i, Europe's leading private equity house, jointly announced today that they have entered into a definitive agreement providing for the strategic investment by Dr. Reddy's to acquire 100% of betapharm Group, the fourth-largest generic pharmaceuticals company in Germany, for a total enterprise value of EUR 480 million in cash. The transaction will be funded using a combination of Dr. Reddy's internal cash reserves and committed credit facilities.

Read at BioSpace.com
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES